{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:51:41Z","timestamp":1747158701312,"version":"3.40.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ctrv.2017.05.007","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T16:30:47Z","timestamp":1497889847000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pros and cons of rituximab maintenance in follicular lymphoma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-4527","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctrv.2017.05.007_b0005","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2017.05.007_b0010","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2017.05.007_b0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.007_b0020","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.007_b0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2017.05.007_b0030","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2017.05.007_b0040","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2015-02-628362","article-title":"Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma","volume":"125","author":"Rashidi","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2017.05.007_b0065","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2017.05.007_b0070","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.ctrv.2017.05.007_b0075","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2017.05.007_b0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III Trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2017.05.007_b0085","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2017.05.007_b0090","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2017.05.007_b0095","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"9759","key":"10.1016\/j.ctrv.2017.05.007_b0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ctrv.2017.05.007_b0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Salles","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2017.05.007_b0115","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2017.05.007_b0120","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2017.05.007_b0125","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-016-2705-z","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience","volume":"95","author":"Bourcier","year":"2016","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.007_b0140","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2017.05.007_b0145","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25 Suppl 3","author":"Dreyling","year":"2014","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO"},{"issue":"4","key":"10.1016\/j.ctrv.2017.05.007_b0150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2017.05.007_b0155","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.007_b0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.007_b0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/2040620711407675","article-title":"Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation","volume":"2","author":"Walker","year":"2011","journal-title":"Therap Adv Hematol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.05.007_b0170","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","article-title":"Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)","volume":"33","author":"Wagner","year":"2015","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.007_b0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2017.05.007_b0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V59.2.258.258","article-title":"Histologic progression in non-Hodgkin's lymphoma","volume":"59","author":"Hubbard","year":"1982","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2017.05.007_b0185","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2017.05.007_b0190","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.05.007_b0195","doi-asserted-by":"crossref","unstructured":"Al-Tourah AJ, Sehn LH, Moccia AA, Gascoyne RD, Connors JM. Transformation of follicular lymphoma in the era of immunochemotherapy: a population-based study from British Columbia. presented at: ASCO Annual Meeting Proceedings; 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.8049"},{"issue":"7","key":"10.1016\/j.ctrv.2017.05.007_b0210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.05.007_b0220","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2017.05.007_b0225","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3109\/10428194.2012.694429","article-title":"Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy","volume":"53","author":"Hornberger","year":"2012","journal-title":"Leukemia lymphoma"},{"issue":"2","key":"10.1016\/j.ctrv.2017.05.007_b0230","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health: J Int Soc Pharm Outcomes Res"},{"issue":"6","key":"10.1016\/j.ctrv.2017.05.007_b0235","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.05.007_b0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","volume":"28","author":"Deconinck","year":"2010","journal-title":"PharmacoEconomics"},{"issue":"5","key":"10.1016\/j.ctrv.2017.05.007_b0245","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12264","article-title":"Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study","volume":"92","author":"Blommestein","year":"2014","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.ctrv.2017.05.007_b0250","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","article-title":"Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study","volume":"32","author":"Salar","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.05.007_b0255","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2017.05.007_b0260","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ctrv.2017.05.007_b0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3111\/13696998.2014.914033","article-title":"Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom","volume":"17","author":"Rule","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.ctrv.2017.05.007_b0270","unstructured":"Rule S, Briones J, Smith R, et al. Preference for rituximab SC and IV among patients with CD20+ NHL completing the Rasq Measure in randomized phase III studies of Prefab and Mabcute."},{"issue":"19","key":"10.1016\/j.ctrv.2017.05.007_b0135","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2017.05.007_b0275","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.ctrv.2017.05.007_b0280","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.05.007_b0285","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2017.05.007_b0290","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 Trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T11:31:15Z","timestamp":1602329475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217300968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":48,"alternative-id":["S0305737217300968"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"type":"print","value":"0305-7372"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pros and cons of rituximab maintenance in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}